Cromos Pharma supporting lung cancer clinical trials
November is Lung Cancer Awareness Month. Lung cancer is the most common cause of cancer death worldwide making up almost 25% of all cancer deaths. Every year, more people die of lung cancer than of colon, breast, and prostate cancers combined. In recent years, clinical research has led to significant breakthroughs in the treatment of lung cancer, giving
Connect with Cromos Pharma at 40th JP Morgan Healthcare Conference
Meet with Cromos Pharma during the 40th JP Morgan Healthcare Conference, January 2022. Cromos Pharma is delighted to be participating again at this prestigious invite-only event. Meet with Cromos Pharma during the 40th JP Morgan Healthcare Conference, January 2022. Cromos Pharma is delighted to be participating again at this prestigious invite-only event. LET OUR EXPERIENCE BENEFIT YOUR
Cromos Pharma making sure your clinical trial is feasible
It is estimated that up to 80% of clinical studies fail to recruit sufficient numbers of participants. These failures waste valuable resources and time as well as delaying new treatments reaching patients. At Cromos Pharma we understand how important it is to conduct robust feasibility assessments of clinical trials to optimize the chances of success.
